BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome: The exploration of BRCA1 and BRCA2 as well as homologous recombination deficient (HRD) has driven the development of targeted therapy for HRD, particularly poly (ADP-ribose) polymerase (PARP) inhibitors.